Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 26 studies | 29% ± 12% | |
endothelial cell | 21 studies | 27% ± 10% | |
mast cell | 20 studies | 36% ± 16% | |
conventional dendritic cell | 19 studies | 31% ± 10% | |
classical monocyte | 17 studies | 33% ± 14% | |
dendritic cell | 12 studies | 33% ± 11% | |
fibroblast | 12 studies | 26% ± 10% | |
monocyte | 11 studies | 27% ± 8% | |
type I pneumocyte | 10 studies | 32% ± 13% | |
endothelial cell of artery | 9 studies | 21% ± 5% | |
secretory cell | 8 studies | 20% ± 3% | |
non-classical monocyte | 8 studies | 23% ± 8% | |
basal cell | 8 studies | 25% ± 9% | |
vein endothelial cell | 8 studies | 24% ± 4% | |
type II pneumocyte | 7 studies | 26% ± 8% | |
mononuclear phagocyte | 7 studies | 33% ± 8% | |
myeloid cell | 7 studies | 29% ± 12% | |
epithelial cell | 7 studies | 31% ± 17% | |
club cell | 7 studies | 31% ± 12% | |
endothelial cell of vascular tree | 7 studies | 22% ± 6% | |
regulatory T cell | 7 studies | 19% ± 3% | |
T cell | 6 studies | 25% ± 6% | |
respiratory goblet cell | 6 studies | 35% ± 16% | |
ciliated cell | 6 studies | 22% ± 10% | |
pericyte | 6 studies | 20% ± 3% | |
endothelial cell of lymphatic vessel | 4 studies | 24% ± 5% | |
GABAergic neuron | 4 studies | 34% ± 18% | |
innate lymphoid cell | 4 studies | 25% ± 3% | |
capillary endothelial cell | 4 studies | 22% ± 4% | |
glial cell | 4 studies | 26% ± 3% | |
intermediate monocyte | 4 studies | 33% ± 14% | |
alveolar macrophage | 4 studies | 26% ± 6% | |
tissue-resident macrophage | 3 studies | 39% ± 29% | |
granulocyte | 3 studies | 24% ± 6% | |
glutamatergic neuron | 3 studies | 43% ± 17% | |
leukocyte | 3 studies | 21% ± 5% | |
gamma-delta T cell | 3 studies | 21% ± 5% | |
group 3 innate lymphoid cell | 3 studies | 45% ± 14% | |
oligodendrocyte | 3 studies | 31% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3534.60 | 1444 / 1445 | 100% | 56.31 | 183 / 183 |
lung | 100% | 7524.90 | 578 / 578 | 100% | 56.69 | 1150 / 1155 |
bladder | 100% | 7436.38 | 21 / 21 | 98% | 60.60 | 495 / 504 |
intestine | 100% | 3279.82 | 965 / 966 | 97% | 27.46 | 509 / 527 |
stomach | 99% | 2796.26 | 356 / 359 | 97% | 29.57 | 276 / 286 |
thymus | 100% | 4191.96 | 652 / 653 | 95% | 37.59 | 575 / 605 |
breast | 100% | 6654.04 | 459 / 459 | 93% | 26.55 | 1045 / 1118 |
uterus | 98% | 2630.43 | 166 / 170 | 92% | 29.19 | 423 / 459 |
skin | 100% | 6083.99 | 1805 / 1809 | 87% | 35.49 | 409 / 472 |
liver | 99% | 2703.72 | 224 / 226 | 87% | 19.79 | 353 / 406 |
ovary | 90% | 2074.38 | 162 / 180 | 94% | 23.48 | 405 / 430 |
prostate | 99% | 3651.41 | 242 / 245 | 64% | 9.23 | 320 / 502 |
kidney | 72% | 1340.76 | 64 / 89 | 90% | 29.14 | 813 / 901 |
pancreas | 53% | 772.19 | 174 / 328 | 97% | 51.72 | 173 / 178 |
adrenal gland | 100% | 3612.13 | 258 / 258 | 42% | 7.98 | 97 / 230 |
adipose | 100% | 6937.06 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 2690.39 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.15 | 1 / 1 |
blood vessel | 100% | 4195.72 | 1330 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 30.56 | 28 / 29 |
tonsil | 0% | 0 | 0 / 0 | 93% | 21.03 | 42 / 45 |
heart | 88% | 1772.36 | 760 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 59% | 1554.08 | 547 / 929 | 0% | 0 | 0 / 0 |
brain | 9% | 118.28 | 240 / 2642 | 33% | 6.16 | 234 / 705 |
muscle | 7% | 91.05 | 58 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0010468 | Biological process | regulation of gene expression |
GO_0002841 | Biological process | negative regulation of T cell mediated immune response to tumor cell |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_1904613 | Biological process | cellular response to 2,3,7,8-tetrachlorodibenzodioxine |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0071219 | Biological process | cellular response to molecule of bacterial origin |
GO_0030522 | Biological process | intracellular receptor signaling pathway |
GO_0019933 | Biological process | cAMP-mediated signaling |
GO_0032922 | Biological process | circadian regulation of gene expression |
GO_0002819 | Biological process | regulation of adaptive immune response |
GO_0030888 | Biological process | regulation of B cell proliferation |
GO_0071320 | Biological process | cellular response to cAMP |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_1904322 | Biological process | cellular response to forskolin |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0001568 | Biological process | blood vessel development |
GO_0006915 | Biological process | apoptotic process |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0009636 | Biological process | response to toxic substance |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0034752 | Cellular component | cytosolic aryl hydrocarbon receptor complex |
GO_0034753 | Cellular component | nuclear aryl hydrocarbon receptor complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0034751 | Cellular component | aryl hydrocarbon receptor complex |
GO_0000785 | Cellular component | chromatin |
GO_0005667 | Cellular component | transcription regulator complex |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0017025 | Molecular function | TBP-class protein binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0000987 | Molecular function | cis-regulatory region sequence-specific DNA binding |
GO_0051879 | Molecular function | Hsp90 protein binding |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0004879 | Molecular function | nuclear receptor activity |
GO_0001094 | Molecular function | TFIID-class transcription factor complex binding |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0001223 | Molecular function | transcription coactivator binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0070888 | Molecular function | E-box binding |
GO_0005515 | Molecular function | protein binding |
Gene name | AHR |
Protein name | Alternative protein AHR Aryl hydrocarbon receptor (Ah receptor) (AhR) (Class E basic helix-loop-helix protein 76) (bHLHe76) Aryl hydrocarbon receptor |
Synonyms | BHLHE76 |
Description | FUNCTION: Ligand-activated transcription factor that enables cells to adapt to changing conditions by sensing compounds from the environment, diet, microbiome and cellular metabolism, and which plays important roles in development, immunity and cancer . Upon ligand binding, translocates into the nucleus, where it heterodimerizes with ARNT and induces transcription by binding to xenobiotic response elements (XRE) . Regulates a variety of biological processes, including angiogenesis, hematopoiesis, drug and lipid metabolism, cell motility and immune modulation . Xenobiotics can act as ligands: upon xenobiotic-binding, activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes (such as the CYP1A1 gene) . Mediates biochemical and toxic effects of halogenated aromatic hydrocarbons . Next to xenobiotics, natural ligands derived from plants, microbiota, and endogenous metabolism are potent AHR agonists . Tryptophan (Trp) derivatives constitute an important class of endogenous AHR ligands . Acts as a negative regulator of anti-tumor immunity: indoles and kynurenic acid generated by Trp catabolism act as ligand and activate AHR, thereby promoting AHR-driven cancer cell motility and suppressing adaptive immunity . Regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1 . Inhibits PER1 by repressing the CLOCK-BMAL1 heterodimer mediated transcriptional activation of PER1 . The heterodimer ARNT:AHR binds to core DNA sequence 5'-TGCGTG-3' within the dioxin response element (DRE) of target gene promoters and activates their transcription . . |
Accessions | ENST00000242057.9 P35869 L0R578 ENST00000642825.1 A0A2R8Y7G1 ENST00000463496.1 |